million conduct beta-th studi year
crispr end million cash rais net proce million
bring pro forma cash million one three european countri
accept conduct phase i/ii beta-th studi ex vivo
ind file sickl cell diseas scd expect first-in-man crispr
data import mileston vertex exercis option
crispr recogn million defer revenu crispr could file ind
allogen ex vivo crispr-modifi car-t crispr
cross-licens ip intellia patent disput edita cover
potenti updat year reiter overweight rate increas
price target appli valu crispr pipelin
data like crispr announc one clinic trial applic
file major european countri accept enabl first-ev
studi start man year phase i/ii studi evalu
ex vivo therapi beta-thalassemia patient compani file ind
scd data show edit effici
human hsc translat clinic meaning ratio fetal hemoglobin
hbf total hb express edit cell believ result demonstr
potenti cur effect view reduc risk upcom phase
i/ii studi first-in-man data serv import driver set potenti
rapid approv beta-th scd blockbust sale potenti
partner vertex exercis option co-develop
crispr-modifi car-t crispr develop allogen ex vivo
crispr-modifi car-t compani transit gmp-manufactur
stage plan file ind treat hematolog malign
autolog cell therapi seen respons rate limit burdensom
manufactur process crispr also develop allogen car-t target
bcma could enter clinic crispr retain global right
immune-oncolog program
patent interfer appeal updat await next decis
appeal patent trial appeal board ptab rule
interfer issu editas/broad institut patent applic file
uc berkeley specul outcom patent lawsuit see
immens therapeut potenti overshadow ip disput
technolog unproven may fail man crispr involv
patent litig could advers effect compani abil conduct busi
compani like requir futur capit
crsp pioneer develop therapeut genom edit
proj ev cash
februari
incl recent financ million
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
invest recommend reiter overweight rate increas price target lower
discount rate beta-thalassemia sickl cell diseas increas valu
ex vivo car-t platform bring project enterpris valu billion
valu beta-thalassemia sickl cell diseas million
million million million appli standard multipl
ebitda million million respect discount back lower
still multipl standard higher margin profit lower discount
rate reflect first accept cta file well expect proof-
of-concept phase i/ii data year
valu crsp ex vivo car-t platform million million reflect
increas valu million car-t program transit
gmp-manufactur stage plan file ind also ad million
valu allogen anti-bcma car-t advanc rapidli
clinic
also increas valu compani casebia joint ventur million
million compani advanc toward clinic multipl program
add project cash million prior million divid
increas project billion market cap million share arriv
page
thousand except per share
research develop
gener administr
loss attribut non-controlling interest
dividend attribut convert prefer stock
net incom alloc particip secur
compani report piper jaffray estim
net loss includ one-tim dividend convert prefer stock class convert unit follow ipo
current disclosur inform compani found
